Evidence map›Paper›PMID 41670928›Full record

ArticleBreast cancer (Tokyo, Japan)2026

FGFR4 and HER2 co-expression is associated with the proinflammatory tumor microenvironment in HR + breast cancer.

Yike Gao, Longyun Chen, Fei Yao, Jin Wang, Changbin Zhu, Shafei Wu, Zhiyong Liang

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yike Gao *Department of Pathology, Molecular Pathology Research Centre, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Longyun Chen *Department of Pathology, Molecular Pathology Research Centre, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Fei YaoMedical Department, Amoy Diagnostics Co., Ltd, Xiamen, Fujian, China.
Jin WangMedical Department, Amoy Diagnostics Co., Ltd, Xiamen, Fujian, China.
Changbin ZhuMedical Department, Amoy Diagnostics Co., Ltd, Xiamen, Fujian, China.
Shafei WuDepartment of Pathology, Molecular Pathology Research Centre, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China. shafei_wu@126.com.
Zhiyong LiangDepartment of Pathology, Molecular Pathology Research Centre, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China. liangzy@pumch.cn.ORCID http://orcid.org/0000-0003-4787-2925

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDysregulated FGFR4 signaling has been associated with aggressive subtypes of breast cancers, characterized by HER2 enrichment or endocrine resistance. However, the biological functions of FGFR4 across breast cancer subtypes remain unclear. This study investigated the molecular characteristics of FGFR4-high tumors to inform potential therapeutic strategies.

methodsThis study analyzed clinicopathological characteristics and gene expression profile of 53 hormone receptor-positive (HR

resultsThe patients in the PUMCH cohort (n = 94) were stratified by HER2 and HR statuses and further stratified according to FGFR4 expression. FGFR4-high tumors showed no genomic differences but enriched immune activation pathways, specifically in HR

conclusionsCo-expression of FGFR4 and HER2 is associated with a proinflammatory tumor microenvironment in HR

Indexed as

Biomarkers, TumorBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesReceptor, Fibroblast Growth Factor, Type 4Tumor MicroenvironmentAgedFemaleGene Expression Regulation, NeoplasticHumansMiddle AgedPrognosisReceptors, EstrogenReceptors, ProgesteroneBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesFGFR4 protein, humanReceptor, Fibroblast Growth Factor, Type 4Receptors, EstrogenReceptors, ProgesteroneBreast cancerFGFR4Hormone receptorImmunotherapyTumor microenvironment

Identifiers

PMID41670928

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.